ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TTRX / news
CYPH (42) ARCT (25) ENTA (20) PRLD (33) ⌘ Pro Terminal →

Why TTRX Stock dropped -7.48% Today — RQD Quant Desk Flash

$9.65 -7.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.50

Turn Therapeutics Inc. (TTRX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $318.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TTRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TTRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Turn Therapeutics Inc. (NASDAQ: TTRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $9.65 (-7.48% 1D, market cap $318.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TTRX ranks #507 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TTRX compare to CYPH and ARCT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TTRX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, CYPH (Cypherpunk Technologies Inc.) holds a D- grade (42/100 RQD, P/E 71.3x, ROIC -23.3%, cap $321.1M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TTRX?
▼

Per TTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023016), Turn Therapeutics Inc. generated $16.4M in revenue (+226.0% YoY), -$3.2M in net income, and -$2.6M in free cash flow against $12.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.50 (-1.54%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (6)Whales (8)SEC (10)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$17 Bull$9 Base$7 Bear
📬 FREE TTRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TTRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY TTRX SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (29% of score)

FRED Regime × Technicals: 51% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$10.60-1.2% Next Q
Q2 (-2Q)
43
Grade D$10.47-0.5% Next Q
Q3 (-1Q)
41
Grade D$10.42-7.4% Next Q
Current
38
Grade D-$9.65-7.8% Hist 90D α
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TTRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TTRX currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.77) and Max Pain ($10.13) forces dealer call-delta covering toward $17.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TTRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TTRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why TTRX Stock dropped -7.48% Today — RQD Quant Desk Flash

Turn Therapeutics Inc. (TTRX) dropped -7.48% to $9.65, trading at 51% of its 52-week range ($2.57 – $16.45). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 51% of its 52-week range ($2.57 – $16.45) with RSI-14 at 43.8 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $9.65 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TTRX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TTRX)

  • ✓Walkthrough of TTRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TTRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +160.11%🛡️ HOLDING TREND SUPPORT
2026-11-03O $10.72H $10.72L $9.65C $9.65VOL 137.1K
RES: $19.44SUP: $9.62SMA50: $11.77SMA200: $7.06
$17.36$13.59$9.83$6.07$2.30RES $19.44SUP $9.62$9.652026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TTRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TTRX Butterfly Map → + Track TTRX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +226.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TTRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TTRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TTRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TTRX)

Health Care Rank #507 of 1015 ⚔️ CYPH vs TTRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TTRX vs. CYPH, ARCT, ENTA, PRLD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Turn Therapeutics Inc. (TTRX) ranks #507 by composite RQD confidence (38/100, grade D-) and #508 by equity capitalization ($318.5M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. CYPH currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with TTRX at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TTRX ACTIVE
Turn Therapeutics Inc.
D- 38/100 — — -28.3% -7.48% $318.5M Benchmark Subject
CYPH
Cypherpunk Technologies Inc.
D- 42/100 71.3x — -23.3% -20.80% $321.1M /cyph-vs-ttrx →
ARCT
Arcturus Therapeutics Holdings Inc.
E 25/100 — — -35.0% -13.96% $313.5M /arct-vs-ttrx →
ENTA
Enanta Pharmaceuticals Inc.
E 20/100 — — -35.0% -2.61% $311.9M /enta-vs-ttrx →
PRLD
Prelude Therapeutics Incorporated
E 33/100 — — -35.0% -1.03% $309.6M /prld-vs-ttrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002023016 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Turn Therapeutics Inc. (TTRX) reported GAAP revenue of $16.4M (+226.0% vs. FY2024 revenue of $5.0M ) , GAAP net income of -$3.2M, operating cash flow of -$2.6M, and free cash flow of -$2.6M (-88.3% YoY). On the balance sheet, TTRX closed FY2025 with $12.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.4M -$3.2M -$2.6M -$2.6M $12.2M —
FY2024 (FY) 2024-12-31 $5.0M -$1.8M -$1.4M -$1.4M $2.0M —

3. TTRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TTRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Turn Therapeutics Inc. (NASDAQ: TTRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $9.65 (-7.48% 1D, market cap $318.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TTRX ranks #507 in composite RQD confidence.

How does TTRX compare to CYPH and ARCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TTRX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, CYPH (Cypherpunk Technologies Inc.) holds a D- grade (42/100 RQD, P/E 71.3x, ROIC -23.3%, cap $321.1M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TTRX?

Per TTRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023016), Turn Therapeutics Inc. generated $16.4M in revenue (+226.0% YoY), -$3.2M in net income, and -$2.6M in free cash flow against $12.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TTRX trading relative to its 50-day, 200-day, and 52-week technical levels?

TTRX last traded at $9.65 (-7.48% on volume of 85,823 shares), positioning the stock -18.01% below its 50-day simple moving average ($11.77) and +36.69% above its 200-day simple moving average ($7.06). Across its 52-week range of $2.57 to $16.45, TTRX sits at the 51.0% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.44 to $10.86).

Direct Sub-Reports: TTRX RQD Cockpit TTRX 12M Forecast TTRX Earnings & Move TTRX Dividends & DRIP TTRX Insiders & 13F TTRX Whale Options TTRX Profit Sankey TTRX News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

TTRX — Turn Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Turn Therapeutics Inc. (TTRX) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.65 (-7.48% 1D, market capitalization $318.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -28.3%, gross margin of —, operating margin of —, and free cash flow yield of -0.78%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Turn Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.3B. The FY 2025 and FY 2024 financials report — in revenue in both periods, indicating no reported revenue in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Turn Therapeutics Inc. (TTRX) reported $16.4M in annual revenue (up from $5.0M in FY2024, +226.0% YoY) and -$3.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($5.0M revenue, -$1.8M net income) through FY2025, TTRX scaled operating cash flow to -$2.6M and free cash flow to -$2.6M, backed by $12.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.78% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $2.57 – $16.45 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TTRX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can TTRX sustain or expand its — operating margin and -28.3% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $16.4M and free cash flow of -$2.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is TTRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TTRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Turn Therapeutics Inc. (TTRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TTRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TTRX Bull vs. Bear Conversation Board — What's Your Call at $9.65?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TTRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TTRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $12.83 (+23.0%)
📌 Pinned Debate

Pipeline catalysts (Phase 2 AD topline due Q1 2027) and a WBB Securities upgrade to Hold with a $10 target could drive re-rating if res

The street is overcomplicating Turn Therapeutics Inc. (TTRX). Pipeline catalysts (Phase 2 AD topline due Q1 2027) and a WBB Securities upgrade to Hold with a $10 target could drive re-rating if results land.. With an RQD score of 38/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $11.26.

RetailWhale_TX 🐂 BULL

Both sides have a point here — TTRX's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $8.97 (-14.0%)
Spot @ $10.43

Negative FCF of -$2.6M, ROIC of -28.3%, and a Piotroski F of 1/9 indicate a cash-consuming business with weak forensic health.

Negative FCF of -$2.6M, ROIC of -28.3%, and a Piotroski F of 1/9 indicate a cash-consuming business with weak forensic health.. Look at the math on TTRX: paying current EV/EBITDA multiples for -28.3% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $9.18 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%